ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by Northern Trust Corp

Key Points

• Northern Trust Corp increased its holdings in ANI Pharmaceuticals by 6.1%, acquiring an additional 12,517 shares to own a total of 216,862 shares valued at approximately $14.5 million.
• ANI Pharmaceuticals reported earnings per share of $1.80 for the last quarter, significantly beating analysts' expectations of $1.42, with year-over-year revenue growth of 53.2%.
• Institutional investors and hedge funds collectively own 76.05% of ANI Pharmaceuticals stock, indicating strong institutional interest in the company's shares.

Northern Trust Corp increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 216,862 shares of the specialty pharmaceutical company's stock after purchasing an additional 12,517 shares during the period. Northern Trust Corp owned approximately 1.00% of ANI Pharmaceuticals worth $14,519,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ANIP. Millennium Management LLC increased its holdings in ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after buying an additional 473,097 shares in the last quarter. Aberdeen Group plc increased its holdings in ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock valued at $28,059,000 after buying an additional 181,134 shares in the last quarter. Deep Track Capital LP increased its holdings in ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after buying an additional 144,214 shares in the last quarter. Global Alpha Capital Management Ltd. increased its holdings in ANI Pharmaceuticals by 17.8% in the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after buying an additional 111,040 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in ANI Pharmaceuticals by 17,558.4% in the first quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after buying an additional 94,464 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on ANIP. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a "buy" rating in a report on Monday. HC Wainwright reaffirmed a "buy" rating and issued a $93.00 target price (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Piper Sandler reissued an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $88.25.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, August 15th. The shares were sold at an average price of $86.97, for a total value of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares in the company, valued at $15,065,465.22. This trade represents a 10.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 50,000 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the completion of the transaction, the chief financial officer owned 180,863 shares in the company, valued at approximately $15,566,878.41. This trade represents a 21.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 412,830 shares of company stock worth $36,382,434 over the last 90 days. Company insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Trading Up 1.1%

ANIP stock traded up $1.04 during midday trading on Tuesday, hitting $96.24. The stock had a trading volume of 109,962 shares, compared to its average volume of 373,980. The firm has a market cap of $2.09 billion, a PE ratio of -124.91 and a beta of 0.63. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $96.90. The company's 50-day moving average price is $76.86 and its 200 day moving average price is $68.62.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals's revenue for the quarter was up 53.2% on a year-over-year basis. During the same quarter last year, the business earned $1.02 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.